A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer.

The purpose of the study is to compare BI 695502 (the study drug) to Avastin.  Avastin has been shown to be effective in patients with a type of lung cancer called non-squamous non-small cell lung cancer (nsNSCLC) in association with chemotherapy.

Contact Candace LeBlanc 508-556-5431 or Marcy Kirkpatrick 508-556-5429 for more information.

For more information about this study: